Hongxiang Ji Zhijian Wen Bin Liu Hongbiao Chen Qian Lin Zhan Chen
10.3389/fimmu.2022.995121
Front Immunol
2022 Aug 26;13:995121.
ici-associated myocarditis (iciam) hepatocellular carcinoma (hcc) immune checkpoint inhibitor-associated adverse reactions (iraes) programmed cell death receptor 1/ligand 1 (pd-1/pd-l1) sintilimab
CC BY
https://pubmed.ncbi.nlm.nih.gov/36091070/
Carcinoma, Hepatocellular / drug therapy Liver Neoplasms / drug therapy Myocarditis
Carcinoma, Hepatocellular / drug therapy Liver Neoplasms / drug therapy Myocarditis Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / adverse effects Humans Antibodies, Monoclonal, Humanized sintilimab
PMC9458972
36091070
Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
2022